Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1345-1351

  Oki, Yasuhiro ^a   Kato, Harumi ^a   Matsuo, Keitaro ^a   Kuwatsuka, Yachiyo ^a   Taji, Hirofumi ^a   Yamamoto, Kazuhito ^a   Kagami, Yoshitoyo ^a   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytokine and chemokine biology; Diffuse large B cell lymphoma; Immunobiology; Lymphoma and Hodgkin disease; Neoplasia; Prognostic factors; Prognostication; Soluble interleukin 2 receptor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFUSE LARGE B CELL LYMPHOMA; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 47649102912     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802108888     Document Type: Article

References (25)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
2. Rubin, L. A., Galli, F., Greene, W. C., Nelson, D. L. and Jay, G. (1990) The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine, 2, pp. 330-336.
3. Wagner, D. K., Kiwanuka, J., Edwards, B. K., Rubin, L. A., Nelson, D. L. and Magrath, I. T. (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. J Clin Oncol, 5, pp. 1262-1274.
4. Harrington, D. S., Patil, K., Lai, P. K., Yasuda, N. N., Armitage, J. O. Ip, S. H. et al. (1988) Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med, 112, pp. 597-601.
5. Yasuda, N., Lai, P. K., Ip, S. H., Kung, P. C., Hinuma, Y. Matsuoka, M. et al. (1988) Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood, 71, pp. 1021-1026.
6. Stasi, R., Conforti, M., Del Poeta, G, Simone, M. D., Coppetelli, U. Tribalto, M. et al. (1992) Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica, 77, pp. 518-521.
7. Kono, N., Kanda, Y., Yamamoto, R., Chizuka, A., Suguro, M. Hamaki, T. et al. (2000) Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: A single center study in Japan. Leuk Lymphoma, 37, pp. 151-156.
8. Niitsu, N., Iijima, K. and Chizuka, A. (2001) A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol, 66, pp. 24-30.
9. Goto, H., Tsurumi, H., Takemura, M., Ino-Shimomura, Y., Kasahara, S. Sawada, M. et al. (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index. J Cancer Res Clin Oncol, 131, pp. 73-79.
10. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. Bouabdallah, R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
11. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M. Imrie, K. et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7, pp. 379-391.
12. Lai, C. K., Chan, C. H., Leung, J. C. and Lai, K. N. (1993) Serum concentration of soluble interleukin 2 receptors in asthma. Correlation with disease activity. Chest, 103, pp. 782-786.
13. Rubin, L. A., Snow, K. M., Kurman, C. C., Nelson, D. L. and Keystone, E. C. (1990) Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: Correlations with disease activity. J Rheumatol, 17, pp. 597-602.
14. Uziel, Y., Krafchik, B. R., Feldman, B., Silverman, E. D., Rubin, L. A. and Laxer, R. M. (1994) Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum, 37, pp. 898-901.
15. Hurteau, J. A., Woolas, R. P., Jacobs, I. J., Oram, D. C., Kurman, C. C. Rubin, L. A. et al. (1995) Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, 76, pp. 1615-1620.
16. Yokose, N., Ogata, K., Ito, T., An, E., Tamura, H. Dan, K. et al. (1994) Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Leuk Res, 18, pp. 777-782.
17. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. Ott, G. et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
18. Muris, J. J., Meijer, C. J., Vos, W., van Krieken, J. H., Jiwa, N. M. Ossenkoppele, G. J. et al. (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, pp. 714-723.
19. Novak, A. J., Grote, D. M., Stenson, M., Ziesmer, S. C., Witzig, T. E. Habermann, T. M. et al. (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood, 104, pp. 2247-2253.
20. Oki, Y., Georgakis, G. V., Migone, T. S., Kwak, L. W. and Younes, A. (2007) Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma, 48, pp. 1869-1871.
21. Aydin, F., Yilmaz, M., Ozdemir, F., Kavgaci, H., Yavuz, M. N. and Yavuz, A. A. (2002) Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol, 25, pp. 570-572.
22. Fabre-Guillevin, E., Tabrizi, R., Coulon, V., Monnereau, A., Eghbali, H. Soubeyran, I. et al. (2006) Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma, 47, pp. 603-611.
23. Stasi, R., Zinzani, L., Galieni, P., Lauta, V. M., Damasio, E. Dispensa, E. et al. (1994) Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer, 74, pp. 1792-1800.
24. Vonderheid, E. C., Zhang, Q., Lessin, S. R., Polansky, M., Abrams, J. T. Bigler, R. D. et al. (1998) Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol, 38, pp. 207-220.
25. Marcon, L., Rubin, L. A., Kurman, C. C., Fritz, M. E., Longo, D. L. Uchiyama, T. et al. (1988) Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy. Ann Intern Med, 109, pp. 274-279.